Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg lowers target price on Valterra Platinum

(Sharecast News) - Analysts at Berenberg lowered their target price on precious metals group Valterra Platinum from 2,600.0p to 2,500.0p on Monday following the release of its Q2 production results and H1 trading statement. Berenberg noted that refined platinum group metals production and sales came in 12% and 8% ahead of its forecasts, respectively, driven by a larger release of work-in-progress inventory.

However, Bernberg said that despite now guiding to the lower end of metal-in-concentrate volumes for 2025 due to flooding at the company's Amandelbult mine, and guiding H1 headline earnings per share to roughly 56% below visible alpha consensus, a strong day for PGM prices helped to lift the shares to close up by 5.8%, which it thinks is unjustified.

Berenberg increased its H1 opex and depreciation expectations, which reduced its FY25 earnings estimates and its price target.

"We update our model for the results and bring our H1 earnings in line with guidance, cutting 2025 EBITDA by 21% and headline EPS by 36%," said the German bank, which also kept its 'sell' rating on the stock.

"The shares are currently trading on 1.47x NAV and 11.9x 2025E EBITDA, and our price target represents 32% downside."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.